Fujifilm Sonosite Inc. subsidiary Fujifilm VisualSonics Inc. said today that it won approval from Health Canada for its Vevo Med ultra-high-frequency clinical ultrasound device.
The device operates at frequencies that are higher than conventional ultrasound devices, enabling healthcare professionals to see sonograms with image resolution down to 30 micrometers.
“Throughout its history, Fujifilm has been at the forefront of extraordinary breakthroughs in healthcare. This powerful technology from Fujifilm VisualSonics is the latest in a long line of innovations,” president & CEO Masayuki Higuchi said in prepared remarks. “With unprecedented image resolution capabilities, Vevo MD will have significant impact on the quality of care Canadian practitioners deliver to patients.”
Vevo MD’s transducer tech operates in a range of frequencies up to 70 MHz, according to Fujifilm VisualSonics.
“It is gratifying to see the Vevo MD make its clinical debut in Canada where Fujifilm partners with numerous world class hospitals,” CMO & senior VP Dr. Diku Mandavia added. “A trailblazing technology, Vevo MD offers Canadian clinicians enormous potential to improve outcomes and change lives.”
In August last year, Fujifilm Holdings (TSE:4901) said that it filed its last Premarket Approval module to the FDA for its Aspire Cristalle breast tomosynthesis optional software upgrade for its Aspire Cristalle digital mammography system.